Effect of Diacerein on Hand Osteoarthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00685542
Recruitment Status : Completed
First Posted : May 28, 2008
Last Update Posted : December 3, 2010
Myungmoon Pharm. Co.
Information provided by:
Seoul National University Hospital

Brief Summary:
Ostearthritis is one of the most common arthritis, affecting more than 30% of aged people world-widely. The disease is characterized by pain and stiffness of the affected joints and is the most common cause of disability in aged people. It commonly affects knee, hip, hand and spine joints. Diacerein is a drug developed specifically for the treatment of osteoarthritis. It has inhibitory effects on interleukin-1 (IL-1) and metalloproteases which are known to play key roles in the pathogenesis of osteoarthritis while exerting no effect on phospholipase A2, cyclooxygenase or lipoxygenase. It showed anti-inflammatory effects on animal models and reduced structural changes in several animal models. Therefore, we investigate the role of diacerein in patients with hand osteoarthritis.

Condition or disease Intervention/treatment Phase
Osteoarthritis Drug: diacerein Drug: placebo Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 86 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase IV Study of Diacerein in Human Hand Osteoarthritis
Study Start Date : June 2008
Actual Primary Completion Date : October 2009
Actual Study Completion Date : December 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis

Arm Intervention/treatment
Experimental: 1
Diacerein 50mg bid
Drug: diacerein
Diacerein 50mg bid
Other Name: Atrodar 50mg bid

Placebo Comparator: 2
placebo 50mg bid
Drug: placebo

Primary Outcome Measures :
  1. Australian/Canadian Osteoarthritis Hand Index (AUSCAN) pain score at 4 week point [ Time Frame: 12 weeks ]

Secondary Outcome Measures :
  1. AUSCAN stiffness score at 4 week point [ Time Frame: 12wks ]
  2. AUSCAN pain score at 12 week point [ Time Frame: 12wk ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Ages over 40 years-old
  • Conforming to the classification criteria of American College of Rheumatology*
  • More than 1 tender joints
  • Self reported hand pain which is more than 30 mm on the Australian/Canadian Osteoarthritis Hand Index visual analogue scales (VAS) after wash out period of 2 weeks

Exclusion Criteria:

  • Pregnant or lactating women
  • Previous history of hypersensitivity to Diacerein
  • Patients who had taken oral corticosteroid or intraarticular steroid to hand joints within 3 months of enrollment
  • Patients who were injected with hyaluronic acid to hand joints within 6 months of enrollment
  • Patients who underwent surgery in any joints of the hands
  • AST/ALT > 2x upper normal range
  • Serum Cr > 1.4 mg/dl
  • Patients who have severe comorbidities such as severe congestive heart failure or pulmonary disease
  • Patients who took oral anticoagulants.
  • Patients who refuse to sign the consent form

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00685542

Korea, Republic of
Seoul National University Hospital
Seoul, Korea, Republic of, 110-744
Sponsors and Collaborators
Seoul National University Hospital
Myungmoon Pharm. Co.
Principal Investigator: Eun Bong Lee, MD Seoul National University Hospital

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Seoul National University Hopital, Eun Bong Lee Identifier: NCT00685542     History of Changes
Other Study ID Numbers: H-081-043-232
First Posted: May 28, 2008    Key Record Dates
Last Update Posted: December 3, 2010
Last Verified: December 2010

Keywords provided by Seoul National University Hospital:

Additional relevant MeSH terms:
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Anti-Inflammatory Agents